The human WRN and BLM RecQ helicases differentially regulate cell proliferation and survival after chemotherapeutic DNA damage.
Loss-of-function mutations in the human RecQ helicase genes WRN and BLM respectively cause the genetic instability/cancer predisposition syndromes Werner syndrome and Bloom syndrome. To identify common and unique functions of WRN and BLM, we systematically analyzed cell proliferation, cell survival, and genomic damage in isogenic cell lines depleted of WRN, BLM, or both proteins. Cell proliferation and survival were assessed before and after treatment with camptothecin, cis-diamminedichloroplatinum(II), hydroxyurea, or 5-fluorouracil. Genomic damage was assessed, before and after replication arrest, by gamma-H2AX staining, which was quantified at the single-cell level by flow cytometry. Cell proliferation was affected strongly by the extent of WRN and/or BLM depletion, and more strongly by BLM than by WRN depletion (P = 0.005). The proliferation of WRN/BLM-codepleted cells, in contrast, did not differ from BLM-depleted cells (P = 0.34). BLM-depleted and WRN/BLM-codepleted cells had comparably impaired survival after DNA damage, whereas WRN-depleted cells displayed a distinct pattern of sensitivity to DNA damage. BLM-depleted and WRN/BLM-codepleted cells had similar, significantly higher gamma-H2AX induction levels than did WRN-depleted cells. Our results provide new information on the role of WRN and BLM in determining cell proliferation, cell survival, and genomic damage after chemotherapeutic DNA damage or replication arrest. We also provide new information on functional redundancy between WRN and BLM. These results provide a strong rationale for further developing WRN and BLM as biomarkers of tumor chemotherapeutic responsiveness.
Mao
Frances J
FJ
Department of Pathology, University of Washington, Seattle, Washington 98195-7705, USA.
Sidorova
Julia M
JM
Lauper
Julia M
JM
Emond
Mary J
MJ
Monnat
Raymond J
RJ
D000970:Antineoplastic Agents / Q000494:pharmacology*; D001859:Bone Neoplasms / Q000188:drug therapy / Q000201:enzymology / Q000235:genetics / Q000473:pathology; D001973:Bromodeoxyuridine / Q000494:pharmacology; D002166:Camptothecin / Q000494:pharmacology; D048708:Cell Growth Processes / Q000502:physiology; D045744:Cell Line, Tumor; D002945:Cisplatin / Q000494:pharmacology; D004249:DNA Damage; D005090:Exodeoxyribonucleases / Q000172:deficiency / Q000378:metabolism*; D005347:Fibroblasts / Q000166:cytology / Q000201:enzymology; D005472:Fluorouracil / Q000494:pharmacology; D006657:Histones / Q000378:metabolism; D006801:Humans; D006918:Hydroxyurea / Q000494:pharmacology; D012516:Osteosarcoma / Q000188:drug therapy / Q000201:enzymology / Q000235:genetics / Q000473:pathology; D053484:RecQ Helicases / Q000172:deficiency / Q000378:metabolism*; D000071657:Werner Syndrome Helicase
D000970:Antineoplastic Agents; C468783:H2AX protein, human; D006657:Histones; D005090:Exodeoxyribonucleases; C097151:Bloom syndrome protein; D053484:RecQ Helicases; C098785:WRN protein, human; D000071657:Werner Syndrome Helicase; D001973:Bromodeoxyuridine; D002945:Cisplatin; D005472:Fluorouracil; D006918:Hydroxyurea; D002166:Camptothecin